In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Elan Pharmaceuticals Inc.

Division of Perrigo Co. PLC
www.elan.com

Latest From Elan Pharmaceuticals Inc.

Nabriva Gains New CEO And Near-Market Antibiotic, Claims Leadership Role

The acquisition of Zavante Therapeutics and its late-stage investigational intravenous antibiotic for use in multi-drug resistant pathogens has also led to C-suite change at Nabriva Therapeutics.

M & A Infectious Diseases

Tysabri Liability: Biogen's Dialogue With FDA Helps Get Suit Tossed

Judge finds Tysabri label warnings about brain infection were adequate and that there is 'clear evidence' FDA would not have approved a labeling change.

Legal Issues Legal Issues

Japan’s Chuikyo Reveals NHI Prices For New Drugs From BMS, Ajinomoto, Novo Nordisk And Others

Sanofi gains 5% price premium for antihistamine Telfast as Japan is hit with strong hay fever season.

BioPharmaceutical Japan

Biopharmaceutical Trends In 2012: Regulatory And Market Strides Paper Over Existential Dilemmas

The biopharma industry enjoyed regulatory success in 2012 that was recognized by investors. The stench from the carcasses of industry’s genericized blockbusters has begun to fade, but R&D productivity for the most part remains poor, expensive late-stage failures abound, and industry is still searching for sustainable business models.

BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Perrigo Co. PLC
  • Senior Management
  • Contact Info
  • Elan Pharmaceuticals Inc.
    Phone: (650) 877-0900
    800 Gateway Blvd.
    S. San Francisco, CA 94080
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register